Novavax’s recombinant quadrivalent flu vaccine candidate (NanoFlu) is being evaluated in an ongoing phase 3 clinical study for use in older adults.
Officials with the FDA have granted Fast Track Designation to Novavax's recombinant quadrivalent seasonal influenza vaccine candidate (NanoFlu), adjuvanted with Matrix-M, in adults aged 65 years and older.1
NanoFlu uses hemagglutinin (HA) amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences.1
The designation is based on an ongoing phase 3 clinical study evaluating the immunogenicity and safety of NanoFlu compared with the quadrivalent formulation of Fluzone. The study aims to demonstrate non-inferior immunogenicity as measured by HA inhibition titers of vaccine homologous influenza strains compared with Fluzone. NanoFlu’s safety profile is also being studied.1
Data from the phase 2 study evaluating NanoFlu in older adults were released in January 2019. The study included 1375 healthy adults 65 years of age and older.
Related: US Adults Forgoing Flu Shot
According to the results:2
According to Novavax, topline results from the phase 3 trial are expected by the end of the first quarter of 2020.1
Sanofi’s Fluzone High-Dose Quadrivalent Influenza Vaccine was approved by the FDA in November 2019 for the prevention of influenza caused by Influenza A subtype viruses and type B viruses in adults 65 years of age and older.
1. Novavax Granted Fast Track Designation for NanoFlu in Older Adults [news release]. Novavax’s website. http://ir.novavax.com/news-releases/news-release-details/novavax-granted-fast-track-designation-nanoflu-older-adults. Accessed January 16, 2020.
2. Novavax Announces Positive Phase 2 NanoFlu Results in Older Adults [news release]. Novavax’s website. http://ir.novavax.com/news-releases/news-release-details/novavax-announces-positive-phase-2-nanoflu-results-older-adults. Accessed January